We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00893269
Recruitment Status : Completed
First Posted : May 5, 2009
Last Update Posted : December 5, 2013
Information provided by (Responsible Party):

Study Description
Brief Summary:
Heavy marijuana users report experiencing trouble sleeping when they try to quit, but this has not been carefully studied. This research is being done to learn more about sleep function in heavy marijuana users, and to determine whether a medication approved for treating insomnia can help restore normal sleep function during brief periods of abstinence.

Condition or disease Intervention/treatment Phase
Marijuana Dependence Drug: eszopiclone Drug: Placebo Drug: ramelteon Drug: zolpidem Phase 1

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep
Study Start Date : October 2008
Primary Completion Date : October 2010
Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Marijuana
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Active Medication
Participants receive active hypnotic medication prior to sleep
Drug: eszopiclone
Oral capsule at dose recommended for adults
Drug: ramelteon
Drug: zolpidem
Placebo Comparator: Placebo
Participants receive placebo prior to sleep
Drug: Placebo
Participants receive placebo prior to sleep

Outcome Measures

Primary Outcome Measures :
  1. Marijuana Withdrawal [ Time Frame: Every day during study participation ]

Secondary Outcome Measures :
  1. Objective Sleep Assessment [ Time Frame: Every day during study participation ]
  2. Cognitive Performance [ Time Frame: Every day during study participation ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • current use of marijuana
  • able to give informed consent

Exclusion Criteria:

  • dependence on drug other than marijuana
  • current sleep disorder
  • pregnant, breast feeding, or planning to become pregnant within the next 3 months
  • currently seeking treatment for cannabis-related problems or otherwise trying to reduce use
  • use of cannabis under the guidance of a physician for a medical disorder
  • unstable or uncontrolled cardiovascular disease (e.g., hypertension, angina)
  • allergy to study medication
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00893269

United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21224
Sponsors and Collaborators
Johns Hopkins University
Food and Drug Administration (FDA)
National Institute on Drug Abuse (NIDA)
Principal Investigator: Ryan Vandrey, Ph.D. Johns Hopkins University
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Ryan Vandrey, Associate Professor, Johns Hopkins University
ClinicalTrials.gov Identifier: NCT00893269     History of Changes
Other Study ID Numbers: NA_00017909
R21DA025794 ( U.S. NIH Grant/Contract )
First Posted: May 5, 2009    Key Record Dates
Last Update Posted: December 5, 2013
Last Verified: December 2013

Keywords provided by Ryan Vandrey, Johns Hopkins University:

Additional relevant MeSH terms:
Marijuana Abuse
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
GABA-A Receptor Agonists
GABA Agonists
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action